Experience of rescue therapy with [Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [Lu]Lu-PSMA-I&T.

Purpose: Radioligand therapy is an increasingly important option for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). Radiohybrid ligands targeting prostate-specific membrane antigen (PSMA) are a novel group of theranostic radioligand therapy agents for which higher tumour absorbed radiation doses have been demonstrated compared to established PSMA ligands. Here, we report data from ten patients who were treated within a compassionate use program with the radiohybrid PSMA-ligand [Lu]Lu-rhPSMA-10.

First Safety and Efficacy Data with the Radiohybrid Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer.

We recently published the first dosimetry data, to our knowledge, for the radioligand therapy agent Lu-rhPSMA-10.1, providing an intrapatient comparison with Lu-PSMA-I&T in patients with metastatic prostate cancer. Here, we report efficacy and safety findings from these patients.

An Intrapatient Dosimetry Comparison of Lu-rhPSMA-10.1 and Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.

As the use of radioligand therapy moves earlier in the prostate cancer timeline, minimizing the absorbed dose to normal organs while maintaining high tumor radiation doses becomes more clinically important because of the longer life expectancy of patients. We performed an intrapatient comparison of pretherapeutic dosimetry with the novel radiohybrid prostate-specific membrane antigen-targeting radiopharmaceutical Lu-rhPSMA-10.1, along with Lu-PSMA-I&T, in patients with metastatic castration-resistant prostate cancer.

[Gender-associated differences in bladder cancer].

Background And Objectives: Although the incidence of bladder cancer among women is lower, they tend to more often have advanced disease at presentation with a more aggressive course. It is still unclear which factors are responsible for the poorer prognosis of bladder cancer in women.

Materials And Methods: Original papers and reviews from 2004 until 2022 were identified in a PubMed search and evaluated.